Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBC-103 intravenous study in previously studied treatment-naive MPS IIIB subjects
2015-001983-20Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lesinidase alfa in mucopolysaccharidosis type IIIB, sponsored by Alexion Pharmaceuticals. Primary endpoint: Safety and tolerability of SBC-103. Started Jun 2015; status: terminated.
02
Drugs
lesinidase alfa
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on 2015-001983-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001983-20.